When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...
KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...